



August 8, 2017

Cumberland Pharmaceutical Reports Double Digit Revenue Growth For The Fourth Consecutive Quarter

- Revenues Grew 17% Over the Prior Year Period
- New Co-Promotion Agreement for Kristalose® added

NASHVILLE, Tenn., Aug. 8, 2017 /PRNewswire/ -- **Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)**, a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced second quarter 2017 financial results with Net Revenues of \$8.7 million, up 17% over the prior year quarter. It was the fourth consecutive quarter of year over year revenue growth for the Company, and during the first half of 2017 Net Revenues increased 21% over the prior year period.



QUARTER HIGHLIGHTS:

- 1 Entered into and launched a new co-promotion agreement for Kristalose®, more than doubling the number of physicians called on in support of the brand.
- 1 Received FDA approval for new Totect® labeling, initiating sales and distribution of the product in the United States.
- 1 Continued to progress Phase II clinical studies for the four advanced pipeline programs.

"We are off to a fine start in 2017, advancing key initiatives toward our goal of delivering long-term sustainable growth," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "For more than a year, we have taken steps to transform Cumberland by adding new products, increasing the number of sales representatives supporting the portfolio, launching new marketing strategies, expanding product labeling, protecting intellectual property, and advancing our clinical pipeline. The result of these efforts has strengthened our market presence, further diversified our revenue stream and led to double digit revenue growth each quarter over the last four quarters. We are hard at work to establish a platform that puts us on a trajectory of sustainable revenue growth and increasing profitability. We are confident, if we execute on our key areas of focus, we can create significant shareholder value."

KEY QUARTER DEVELOPMENTS:

Kristalose®

On April 26, 2017, Cumberland and Poly Pharmaceuticals, Inc. ("Poly"), a privately-held U.S. specialty pharmaceutical company, announced a co-promotion partnership for Kristalose® in the United States. Poly's sales efforts will more than double the number of nationwide physicians called upon in support of the product.

This multi-year co-promotion partnership will expand the promotional support for Kristalose to new medical specialties across the United States. Poly's sales organization will promote the brand's features, provide amplified communication and introduce Kristalose to thousands of additional medical professionals. Cumberland will continue to manage national marketing, distribution, regulatory, and medical support for the brand.

Totect®

Cumberland announced FDA approval of new labeling of Totect® (dexrazoxane hydrochloride). As a result, Cumberland initiated sales and distribution of its second oncology support product for the U.S.

Totect is an FDA-approved emergency oncology intervention which is indicated to treat the toxic effects of extravasation

associated with anthracycline chemotherapy. Extravasation occurs when an injected medicine escapes from the blood vessels and circulates into surrounding tissues in the body causing severe damage and serious complications. Totect can limit such damage without the need for additional surgeries and procedures, enabling patients to continue their essential anti-cancer treatment.

Totect is the second product to emerge from Cumberland's strategic alliance with the Clinigen Group plc. Cumberland is responsible for all marketing, promotion, and distribution of the brand in the United States, while Clinigen manages the manufacturing and regulatory activities for the product.

FINANCIAL RESULTS:

Net Revenue: For the three months ended June 30, 2017, net revenues were \$8.7 million, a 17% increase compared to \$7.4 million for the prior year period. Net revenue by product for the three months ended June 30, 2017, included \$2.9 million for Kristalose[®], \$2.1 million for Ethyol[®], \$1.7 million for Acetadote[®] (including the brand and Company's Authorized Generic) \$1.1 million for Caldolor[®], \$0.4 million for Omeclamox[®]-Pak, and \$0.3 million for Vaprisol[®].

Operating Expenses: Total operating expenses for the three months ended June 30, 2017 were \$10.3 million, compared to \$7.5 million during the prior year period. The primary reasons for this increase were the additional cost of goods sold and royalty expenses associated with the growth in sales.

Earnings: Net income (loss) for the second quarter 2017 was \$(5.2) million or \$(0.32) per diluted share, compared to \$(0.05) million or \$0.00 a share for the prior year period. This difference was impacted by a non-cash charge to taxes associated with an increase in the valuation allowance for the Company's deferred tax assets.

Adjusted Earnings (loss) for the second quarter were \$(0.7) million or \$(0.05) per diluted share, compared to \$0.7 million or \$0.04 per diluted share for the prior year period. The definition and reconciliation of Adjusted Earnings (loss) to net income (loss) is provided in this release.

Balance Sheet: At June 30, 2017, Cumberland had \$49.0 million in cash and marketable securities, including approximately \$34.6 million in cash and equivalents. Total Assets at June 30, 2017 were \$87.8 million. Total Liabilities were \$21.3 million, including \$6.7 million outstanding on the Company's revolving line of credit, resulting in Total Shareholder's Equity of \$66.7 million.

Cumberland also has approximately \$44 million in tax net operating loss carryforwards, resulting from the prior exercise of stock options.

Conference Call and Webcast

A conference call and live Internet webcast will be held on Tuesday, August 8, 2017 at 4:30 p.m. Eastern Time to discuss the Company's second quarter 2017 financial results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406 (for international callers). The Conference ID for the rebroadcast is 48389040. The live webcast and rebroadcast can be accessed via Cumberland's website at <http://investor.shareholder.com/cpix/events.cfm>.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care. The Company develops, acquires, and commercializes brands for the hospital acute care, gastroenterology, and oncology market segments.

The Company's portfolio of FDA approved brands includes:

- 1 **Acetadote[®]** (*acetylcysteine*) Injection, for the treatment of acetaminophen poisoning;
- 1 **Caldolor[®]** (*ibuprofen*) Injection, for the treatment of pain and fever;
- 1 **Kristalose[®]** (*lactulose*) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation;
- 1 **Omeclamox[®]-Pak**, (*omeprazole, clarithromycin, amoxicillin*) for the treatment of *Helicobacter pylori* (*H. pylori*) infection and related duodenal ulcer disease;
- 1 **Vaprisol[®]** (*conivaptan*) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;
- 1 **Ethyol[®]** (*amifostine*) Injection, for the reduction of xerostomia (dry mouth) in patients undergoing post-operative

radiation treatment for head and neck cancer and the renal toxicity associated with the administration of cisplatin in patients with advanced ovarian cancer;

- 1 **Totect**[®] (*dexrazoxane hydrochloride*) Injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy in case of extravasation (drug leakage from the bloodstream into the tissues).

Cumberland's pipeline of product candidates includes:

- 1 **Hepatoren**[®] (*ifetroban*) Injection, a Phase II candidate for the treatment of critically ill patients suffering from liver and kidney failure associated with hepatorenal syndrome ("HRS");
- 1 **Boxaban**[®] (*ifetroban*) oral capsules, a Phase II candidate for the treatment of asthma patients with aspirin-exacerbated respiratory disease ("AERD");
- 1 **Vascular**[™] (*ifetroban*) oral capsules, a Phase II candidate for the treatment of patients with the systemic sclerosis (SSc) form of autoimmune disease;
- 1 **Portaban**[™] (*ifetroban*) oral formulation, a Phase II candidate for the treatment of patients with portal hypertension associated with liver disease;
- 1 **Methotrexate** (*methotrexate*) Injection, an approval submission candidate for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as severe disabling psoriasis.

For more information on Cumberland's approved products, including full prescribing information, please visit the individual product websites, links to which can be found on the Company's website www.cumberlandpharma.com.

About Acetadote[®] (acetylcysteine) Injection

Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is approved in the United States to treat overdose of acetaminophen, a common ingredient in many over-the-counter medications. Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. Serious anaphylactoid reactions, including death in a patient with asthma, have been reported in patients administered acetylcysteine intravenously. Acetadote should be used with caution in patients with asthma or where there is a history of bronchospasm. The total volume administered should be adjusted for patients weighing less than 40 kg and for those requiring fluid restriction. To avoid fluid overload, the volume of diluent should be reduced as needed. If volume is not adjusted, fluid overload can occur, potentially resulting in hyponatremia, seizure and death. For full prescribing information, visit www.acetadote.com.

About Caldolor[®] (ibuprofen) Injection

Caldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor. For full prescribing information, including boxed warning, visit www.caldolor.com.

About Kristalose[®] (lactulose) Oral Solution

Kristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia and hypernatremia. Nausea and vomiting have been reported. Use with caution in diabetics. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing information, visit www.kristalose.com.

About Omeclamox[®]-Pak (omeprazole, clarithromycin, amoxicillin)

Omeprazole is an antisecretory drug, which works by decreasing the amount of acid the stomach produces. Clarithromycin and amoxicillin are antibacterial drugs, which inhibit the growth of bacteria allowing the stomach lining to heal. Omeclamox-

Pak is contraindicated in patients with a history of hypersensitivity to omeprazole, any macrolide antibiotic or penicillin. The safety and effectiveness of Omeclamox-Pak in the pediatric population has not yet been established. Omeclamox-Pak was approved by the U.S. Food and Drug Administration in 2011. For full prescribing information, visit www.omeclamox.com.

About Vaprisol[®] (conivaptan hydrochloride) Injection

Vaprisol is an intravenous treatment for hyponatremia used in the critical care setting. Hyponatremia is an electrolyte disturbance in which sodium ion concentration in blood plasma is lower than normal. This can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia. The product is a vasopressin receptor antagonist that raises serum sodium levels and promotes freewater secretion. Vaprisol was approved by the U.S. Food and Drug Administration in 2005 for euvolemic hyponatremia and in 2007 for hypervolemic hyponatremia. For full prescribing information, visit www.vaprisol.com.

About Ethyol[®] (amifostine) Injection

Ethyol is indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer. It is indicated to reduce the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands.

About Totect[®] (dexrazoxane) Injection

Totect is an anthracycline extravasation agent approved by the United States Food and Drug Administration. Anthracyclines are used to treat many types of cancer and are among the most common cancer therapies.

Anthracycline extravasation occurs when there is accidental leaking of the intravenously-administered medication into the surrounding tissues. Anthracycline extravasation can result in serious complications for cancer patients including tissue necrosis with skin ulceration. In addition to tissue damage, an anthracycline extravasation may cause damage to the nerves, tendons, muscle, and joints. For more information please visit www.totect.com.

About Cumberland Emerging Technologies (CET)

Cumberland Emerging Technologies, Inc. (www.cet-fund.com) is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN, and Gloria Pharmaceuticals. The mission of CET is to advance biomedical technologies and products conceived at Vanderbilt University and other regional research centers towards the marketplace. CET helps manage the development and commercialization process for select projects, and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET's Life Sciences Center, provides laboratory space, equipment and infrastructure for CET's activities and other early-stage life sciences ventures.

Forward-Looking Statements

This announcement contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's most recent Annual Report on Form 10-K and subsequent reports on Form 10-Q as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.

	<u>June 30, 2017</u>	<u>December 31, 2016</u>
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 34,616,105	\$ 34,510,330
Marketable securities	14,356,326	15,622,111
Accounts receivable, net of allowances	6,106,915	7,330,127
Inventories, net	5,554,324	5,371,729
Other current assets	2,659,483	2,710,967
Total current assets	<u>63,293,153</u>	<u>65,545,264</u>
Property and equipment, net	495,328	464,454
Intangible assets, net	21,812,015	22,154,176
Other assets	2,202,296	2,120,742
Deferred tax assets, net	—	3,119,930
Total assets	<u><u>\$ 87,802,792</u></u>	<u><u>\$ 93,404,566</u></u>
LIABILITIES AND EQUITY		
Current liabilities:		
Accounts payable	\$ 6,411,517	\$ 8,036,611
Other current liabilities	6,569,773	6,755,652
Total current liabilities	<u>12,981,290</u>	<u>14,792,263</u>
Revolving line of credit	6,700,000	4,100,000
Other long-term liabilities	1,627,946	1,391,484
Total liabilities	<u>21,309,236</u>	<u>20,283,747</u>
Commitments and contingencies		
Equity:		
Shareholders' equity:		
Common stock—no par value; 100,000,000 shares authorized; 15,937,595 and 16,074,176 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively	53,403,852	54,643,268
Retained earnings	13,252,798	18,604,931
Total shareholders' equity	<u>66,656,650</u>	<u>73,248,199</u>
Noncontrolling interests	(163,094)	(127,380)
Total equity	<u>66,493,556</u>	<u>73,120,819</u>
Total liabilities and equity	<u><u>\$ 87,802,792</u></u>	<u><u>\$ 93,404,566</u></u>

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations and Comprehensive Income (loss)
(Unaudited)

	<u>Three months ended June 30,</u>		<u>Six months ended June 30,</u>	
	<u>2017</u>	<u>2016</u>	<u>2017</u>	<u>2016</u>
Net revenues	\$ 8,667,127	\$ 7,414,835	\$ 18,303,882	\$ 15,152,367
Costs and expenses:				
Cost of products sold	1,668,926	1,155,261	3,050,423	2,379,200
Selling and marketing	4,654,933	3,272,279	9,947,953	6,971,241
Research and development	1,080,426	678,780	1,978,789	1,385,252
General and administrative	2,353,140	1,874,396	4,463,373	3,952,368
Amortization	590,573	539,428	1,202,017	1,070,198
Total costs and expenses	<u>10,347,998</u>	<u>7,520,144</u>	<u>20,642,555</u>	<u>15,758,259</u>
Operating income (loss)	(1,680,871)	(105,309)	(2,338,673)	(605,892)
Interest income	69,481	31,483	122,016	108,612
Interest expense	(30,029)	(28,247)	(61,744)	(48,689)
Income (loss) before income taxes	(1,641,419)	(102,073)	(2,278,401)	(545,969)
Income tax (expense) benefit	(3,535,783)	41,135	(4,192,370)	216,474
Net income (loss)	(5,177,202)	(60,938)	(6,470,771)	(329,495)
Net loss at subsidiary attributable to noncontrolling interests	16,591	12,894	35,714	28,340
Net income (loss) attributable to common shareholders	<u><u>\$ (5,160,611)</u></u>	<u><u>\$ (48,044)</u></u>	<u><u>\$ (6,435,057)</u></u>	<u><u>\$ (301,155)</u></u>
Earnings (loss) per share attributable to common shareholders				
- basic	\$ (0.32)	\$ —	\$ (0.40)	\$ (0.02)
- diluted	\$ (0.32)	\$ —	\$ (0.40)	\$ (0.02)

Weighted-average shares outstanding				
- basic	16,011,758	16,247,028	16,026,935	16,293,744
- diluted	16,011,758	16,247,028	16,026,935	16,293,744
Comprehensive income (loss) attributable to common shareholders	(5,160,611)	(48,044)	(6,435,057)	(301,155)
Net loss at subsidiary attributable to noncontrolling interests	16,591	12,894	35,714	28,340
Total comprehensive income (loss)	<u>\$ (5,177,202)</u>	<u>\$ (60,938)</u>	<u>\$ (6,470,771)</u>	<u>\$ (329,495)</u>

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(Unaudited)

	<u>Six months ended June 30,</u>	
	<u>2017</u>	<u>2016</u>
Cash flows from operating activities:		
Net income (loss)	\$ (6,470,771)	\$ (329,495)
Adjustments to reconcile net income (loss) to net cash used in operating activities:		
Depreciation and amortization expense	1,314,293	1,171,437
Deferred tax expense	4,293,963	533,067
Share-based compensation	551,255	408,226
Excess tax (benefit) expense derived from exercise of stock options	(91,109)	835,016
Noncash interest expense	51,216	37,323
Noncash investment gains	(18,706)	(51,213)
Net changes in assets and liabilities affecting operating activities:		
Accounts receivable	1,223,213	1,526,175
Inventories	(182,595)	(651,538)
Other current assets and other assets	(81,286)	(97,871)
Accounts payable and other current liabilities	(1,920,653)	(4,061,546)
Other long-term liabilities	240,185	136,483
Net cash used in operating activities	<u>(1,090,995)</u>	<u>(543,936)</u>
Cash flows from investing activities:		
Additions to property and equipment	(143,150)	(70,454)
Purchases of marketable securities	(1,201,895)	(2,959,285)
Proceeds from sale of marketable securities	2,486,386	3,009,459
Additions to intangible assets	(753,900)	(1,077,547)
Net cash provided by (used in) investing activities	<u>387,441</u>	<u>(1,097,827)</u>
Cash flows from financing activities:		
Net borrowings on line of credit	2,600,000	1,800,000
Excess tax expense derived from exercise of stock options	—	(835,016)
Repurchase of common shares	(1,790,671)	(1,689,040)
Net cash provided by (used in) financing activities	<u>809,329</u>	<u>(724,056)</u>
Net increase (decrease) in cash and cash equivalents	105,775	(2,365,819)
Cash and cash equivalents at beginning of period	34,510,330	38,203,059
Cash and cash equivalents at end of period	<u>\$ 34,616,105</u>	<u>\$ 35,837,240</u>

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES

Reconciliation of Net Income (loss) Attributable to Common Shareholders to Adjusted Earnings (loss) and Adjusted Diluted Earnings (loss) Per Share
(Unaudited)

	<u>Three months ended June 30,</u>		<u>Three months ended June 30,</u>	
	<u>2017</u>		<u>2016</u>	
	Earnings impact	Earnings per share impact	Earnings impact	Earnings per share impact
Net income (loss) attributable to common shareholders	\$ (5,160,611)	\$ (0.32)	\$ (48,044)	\$ —
Less: Net loss at subsidiary attributable to noncontrolling interests	16,591	—	12,894	—
Net income (loss)	<u>(5,177,202)</u>	<u>(0.32)</u>	<u>(60,938)</u>	<u>—</u>

Adjustments to net income (loss)				
Income tax	3,535,783	0.22	(41,135)	—
Depreciation and amortization	652,808	0.04	589,344	0.04
Share-based compensation (a)	296,670	0.02	233,448	0.01
Interest income	(69,481)	—	(31,483)	—
Interest expense	30,029	—	28,247	—
Adjusted Earnings (loss) and Adjusted Diluted Earnings (loss) Per Share	\$ (731,393)	\$ (0.05)	\$ 717,483	\$ 0.04

Diluted weighted-average common shares outstanding: 16,011,758 16,523,680

	Six months ended June 30, 2017		Six months ended June 30, 2016	
	Earnings impact	Earnings per share impact	Earnings impact	Earnings per share impact
Net income (loss) attributable to common shareholders	\$ (6,435,057)	\$ (0.40)	\$ (301,155)	\$ (0.02)
Less: Net loss at subsidiary attributable to noncontrolling interests	35,714	—	28,340	—
Net income (loss)	(6,470,771)	(0.40)	(329,495)	(0.02)
Adjustments to net income (loss)				
Income tax expense (benefit)	4,192,370	0.26	(216,474)	(0.01)
Depreciation and amortization expense	1,314,293	0.08	1,171,437	0.07
Share-based compensation (a)	551,255	0.03	408,226	0.03
Interest income	(122,016)	(0.01)	(108,612)	(0.01)
Interest expense	61,744	—	48,689	—
Adjusted Earnings (loss) and Adjusted Diluted Earnings (loss) Per Share	\$ (473,125)	\$ (0.03)	\$ 973,771	\$ 0.06

Diluted weighted-average common shares outstanding: 16,026,935 16,622,448

The Company provided the above adjusted supplemental financial performance measures, which are considered "non-GAAP" financial measures under applicable Securities and Exchange Commission rules and regulations. These financial measures should be considered supplemental to, and not as a substitute for, financial information prepared in accordance with Generally Accepted Accounting Principles ("GAAP"). The definition of these supplemental measures may differ from similarly titled measures used by others.

Because these supplemental financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the supplemental financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.

Cumberland's management believes these supplemental financial performance measures are important as they are used by management, along with financial measures in accordance with GAAP, to evaluate the Company's operating performance. In addition, Cumberland believes that they will be used by certain investors to measure the Company's operating results. Management believes that presenting these supplemental measures provides useful information about the Company's underlying performance across reporting periods on a consistent basis by excluding items that Cumberland does not believe are indicative of its core business performance or reflect long-term strategic activities. Certain of these items are not settled through cash payments and include: depreciation, amortization, share-based compensation expense and income taxes. Cumberland utilizes its net operating loss carryforwards to pay minimal income taxes. In addition, the use of these financial measures provides greater transparency to investors of supplemental information used by management in its financial and operational decision-making, including the evaluation of the Company's operating performance.

The Company defines these supplemental financial measures as follows:

- 1 **Adjusted Earnings (loss):** net income (loss) adjusted for the impact of income taxes, depreciation and amortization expense, share-based compensation and interest income and interest expense.

(a) Represents the share-based compensation of Cumberland.

- 1 **Adjusted Diluted Earnings (loss) Per Share:** Adjusted Earnings (loss) divided by diluted weighted-average

common shares outstanding.

View original content:<http://www.prnewswire.com/news-releases/cumberland-pharmaceutical-reports-double-digit-revenue-growth-for-the-fourth-consecutive-quarter-300500892.html>

SOURCE Cumberland Pharmaceuticals Inc.

News Provided by Acquire Media